Clinical response to a 12 month histrelin hydrogel implant for the treatment of prostate cancer

Proceedings of the Controlled Release Society

Volumn , Issue 25, 1998, Pages 64-65

  Moo Young, A J ^a   Kuzma, P ^a   Quandt, H ^a   Schlegel, P N ^a   Bardin, C W ^a   Frick, J ^a   Nash, H ^a  

^a Hydro Med Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTRELIN; LUTEINIZING HORMONE; TESTOSTERONE;

CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG IMPLANT; HUMAN; HYDROGEL; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

EID: 0031818536     PISSN: 10220178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)